Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 28 articles: HTML format

Single Articles

January 2023
1. CHU CE, Leapman MS, Zhao S, Cowan JE, et al
   Prostate cancer disparities among American Indians/Alaskan Natives in the United States.
   J Natl Cancer Inst. 2023 Jan 11:djad002. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. HAIMAN CA, Kote-Jarai Z, Darst BF, Conti DV, et al
   RE: Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
   J Natl Cancer Inst. 2023 Jan 11:djad005. doi: 10.1093.
   PubMed    
   
   
   
3. HOULAHAN KE, Livingstone J, Fox NS, Kurganovs N, et al
   A polygenic two-hit hypothesis for prostate cancer.
   J Natl Cancer Inst. 2023 Jan 5:djad001. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2022
4. HU X, Lipscomb J, Jiang C, Graetz I, et al
   Vertical integration of oncologists and cancer outcomes and costs in metastatic Castration-Resistant prostate cancer.
   J Natl Cancer Inst. 2022 Dec 30:djac233. doi: 10.1093.
   PubMed     Abstract available
   
   
   November 2022
5. 
   Correction to: RE: Grade Migration of Prostate Cancer in the United States During the Last Decade.
   J Natl Cancer Inst. 2022 Nov 15. pii: 6827851. doi: 10.1093.
   PubMed    
   
   
   October 2022
6. PAGADALA MS, Lynch J, Karunamuni R, Alba PR, et al
   Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.
   J Natl Cancer Inst. 2022 Oct 28. pii: 6777270. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. SHIH YT, Xu Y, Bradley C, Giordano SH, et al
   Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.
   J Natl Cancer Inst. 2022;114:1392-1399.
   PubMed     Abstract available
   
   
   September 2022
8. AWASTHI S, Grass GD, Torres-Roca J, Johnstone PAS, et al
   Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease.
   J Natl Cancer Inst. 2022 Sep 2. pii: 6687132. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2022
9. TAKAHASHI T
   RE: Grade Migration of Prostate Cancer in the United States during the last decade.
   J Natl Cancer Inst. 2022 Jul 26. pii: 6650145. doi: 10.1093.
   PubMed    
   
   
   June 2022
10. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed     Abstract available
    
    
    April 2022
11. LAI LY, Oerline MK, Caram MEV, Tsao PA, et al
    Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. KEATING NL
    Cardiovascular and Metabolic Diagnoses Associated with Novel Hormonal Agents for Prostate Cancer in Non-Trial Populations.
    J Natl Cancer Inst. 2022 Apr 13. pii: 6568021. doi: 10.1093.
    PubMed    
    
    
    
13. QIAO EM, Lynch JA, Lee KM, Kotha NV, et al
    Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
    J Natl Cancer Inst. 2022;114:592-599.
    PubMed     Abstract available
    
    
    March 2022
14. BORREGALES LD, DeMeo G, Gu X, Cheng E, et al
    Grade Migration of Prostate Cancer in the United States during the last decade.
    J Natl Cancer Inst. 2022 Mar 28. pii: 6555003. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
15. MARK M, von Moos R, Cathomas R, Stoffel S, et al
    RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Nov 29. pii: 6446038. doi: 10.1093.
    PubMed    
    
    
    October 2021
16. MITCHELL AP, Mishra A, Panageas KS, Lipitz-Snyderman A, et al
    Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    J Natl Cancer Inst. 2021 Oct 1. pii: 6379715. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
17. BARNES DR, Silvestri V, Leslie G, McGuffog L, et al
    Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329642. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. HAWLEY JE, Pan S, Kandadi H, Chaimowitz MG, et al
    Analysis of Circulating Immune Biomarkers by Race in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Sipuleucel-T.
    J Natl Cancer Inst. 2021 Jul 24. pii: 6327691. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. KIELY M, Milne GL, Minas TZ, Dorsey TH, et al
    Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men.
    J Natl Cancer Inst. 2021 Jul 15. pii: 6321959. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
20. BRAWLEY OW, Paller CJ
    The Realities of Prostate Cancer Screening, Treatment, and Race.
    J Natl Cancer Inst. 2021 May 8. pii: 6272521. doi: 10.1093.
    PubMed    
    
    
    
21. NYAME YA, Gulati R, Heijnsdijk EAM, Tsodikov A, et al
    The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis.
    J Natl Cancer Inst. 2021 May 8. pii: 6272520. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. OLSSON H, Nordstrom T, Jaderling F, Egevad L, et al
    Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS).
    J Natl Cancer Inst. 2021;113:632-640.
    PubMed     Abstract available
    
    
    
23. BECKER DJ, Rude T, Walter D, Wang C, et al
    The Association of Veterans' PSA Screening Rates With Changes in USPSTF Recommendations.
    J Natl Cancer Inst. 2021;113:626-631.
    PubMed     Abstract available
    
    
    April 2021
24. KLEBANER D, Travis Courtney P, Garraway IP, Einck J, et al
    Association of Health-Care System with Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men.
    J Natl Cancer Inst. 2021 Apr 21. pii: 6248098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. WANG L, Paller C, Hong H, Rosman L, et al
    Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis.
    J Natl Cancer Inst. 2021 Apr 8. pii: 6217361. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2020
26. HEWITT SM
    The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making.
    J Natl Cancer Inst. 2020;112:1079-1080.
    PubMed    
    
    
    October 2020
27. FEDEWA SA, Ma J, Jemal A
    Response to Lehrer and Rheinstein.
    J Natl Cancer Inst. 2020;112:1069-1070.
    PubMed    
    
    
    September 2020
28. BROWN DW, Machiela MJ
    Why Y? Downregulation of Chromosome Y Genes Potentially Contributes to Elevated Cancer Risk.
    J Natl Cancer Inst. 2020;112:871-872.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: